DiaMedica Therapeutics Inc. plans to voluntarily delist its voting common shares from the TSX Venture Exchange.
The clinical-stage biopharmaceutical company's common stock is will be delisted from the exchange at the close of business on Jan. 18.
DiaMedica, which closed its U.S. IPO on Nasdaq in December 2018, will continue to be listed for trading on the Nasdaq Capital Market under the trading symbol DMAC.
Minneapolis-based DiaMedica said in its Jan. 9 news release that the financial and administrative expenses related to maintaining a dual listing were not justified.
DiaMedica, which focuses on the development of treatments for neurological and kidney diseases, stated that the continued listing of its common shares on Nasdaq provides its Canadian shareholders with a sufficiently liquid market.